drugset / Trial / NCT05199519
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345
NaSingle-groupOpen-labelTreatment
Summary
A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors
Timeline
- Start
- 2021-12-13
- Primary completion
- 2022-10-29
- Completion
- 2023-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI345 | Cell therapy | — | Intravenous |